News | July 31, 2025
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Subscribe To Our Newsletter & Stay Updated
